Refine Search

New Search

Results: 3,074

(searched for: publisher_id:101)
Save to Scifeed
Page of 62
Articles per Page
by
Show export options
  Select all
, Alice Shapiro, Karen K. Swenson
Published: 1 February 2011
Clinical Breast Cancer, Volume 11, pp 52-60; doi:10.3816/cbc.2011.n.009

The publisher has not yet granted permission to display this abstract.
, Deborah Ann Thomas, Susan O'Brien, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Alessandra Ferrajoli, , MD, PhD, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 54-59; doi:10.3816/clml.2011.n.007

The publisher has not yet granted permission to display this abstract.
, Patricia Maiso, Abdelkareem Azab, Feda Azab, Yong Zhang, Yang Liu, Hai T. Ngo, Brittany Morgan, Phong Quang, Ghayas Issa, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 109-111; doi:10.3816/clml.2011.n.022

The publisher has not yet granted permission to display this abstract.
, Yong Zhang, Yang Liu, Hai Ngo, Feda Azab, , Abdelkareem Azab, Patricia Maiso, Brittany Morgan, Phong Quang, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 118-120; doi:10.3816/clml.2011.n.025

The publisher has not yet granted permission to display this abstract.
Jenny Y. Sun, Lian Xu, Hsuyi Tseng, Bryan Ciccarelli, Mariateresa Fulciniti, , Kaveh Maghsoudi, Evdoxia Hatjiharissi, Yangsheng Zhou, Guang Yang, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 152-156; doi:10.3816/clml.2011.n.036

The publisher has not yet granted permission to display this abstract.
Bryan T. Ciccarelli, Christopher J. Patterson, Zachary R. Hunter, Christina Hanzis, Leukothea Ioakimidis, Robert Manning, Guang Yang, Lian Xu, Yangsheng Zhou, Jenny Sun, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 160-163; doi:10.3816/clml.2011.n.038

The publisher has not yet granted permission to display this abstract.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 10-16; doi:10.3816/clml.2011.n.001

The publisher has not yet granted permission to display this abstract.
, King H. Lam, Bronno Van Der Holt, Clara Koss, Dennis Veldhuizen, Leo M. Budel, Andries H. Mulder, Leo F. Verdonck, Ruud Delwel, Daphne De Jong, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 23-32; doi:10.3816/clml.2011.n.003

The publisher has not yet granted permission to display this abstract.
, Pieter Sonneveld, Jesús F. San Miguel, Heather J. Sutherland, , Arnon Nagler, Andrew Spencer, Tadeusz Robak, Keith C. Lantz, Sen H. Zhuang, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 44-49; doi:10.3816/clml.2011.n.005

The publisher has not yet granted permission to display this abstract.
, Hlíf Steingrímsdóttir, Vilhelmína Haraldsdóttir
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 82-84; doi:10.3816/clml.2011.n.014

The publisher has not yet granted permission to display this abstract.
, Georgia Levidou, Penelope Korkolopoulou, Efstathios Koulieris, Vassiliki Bartzi, Dimitrios Maltezas, Gerassimos A. Pangalis, Christina Kalpadakis, Maria Dimou, George Georgiou, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 99-102; doi:10.3816/clml.2011.n.019

The publisher has not yet granted permission to display this abstract.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 136-138; doi:10.3816/clml.2011.n.031

The publisher has not yet granted permission to display this abstract.
, Rachel Sexton, John Crowley, Bart Barlogie
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 139-142; doi:10.3816/clml.2011.n.032

The publisher has not yet granted permission to display this abstract.
R G Owen, A G Bynoe, A Varghese, R.M. De Tute,
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 176-179; doi:10.3816/clml.2011.n.042

The publisher has not yet granted permission to display this abstract.
, , Marie-Christine Kyrtsonis, Michael Michael, Evdoxia Hadjiharissi, , Eurydiki Michalis, Panagiotis Repoussis, Konstantinos Tsatalas, Anastasia Sioni, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 127-129; doi:10.3816/clml.2011.n.028

The publisher has not yet granted permission to display this abstract.
, Constantine S. Mitsiades, Kenneth C. Anderson, Paul G. Richardson
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 17-22; doi:10.3816/clml.2011.n.002

The publisher has not yet granted permission to display this abstract.
, Christina Hanzis, Christina Tripsas, Leukothea Ioakimidis, Christopher J. Patterson, Robert J. Manning, Patricia Sheehy
Clinical Lymphoma Myeloma and Leukemia, Volume 11, pp 133-135; doi:10.3816/clml.2011.n.030

The publisher has not yet granted permission to display this abstract.
, Thomas Cosgriff, Graydon Harker, Mark Keaton, Tarek Chidiac, Myo Min
Published: 1 January 2011
Clinical Breast Cancer, Volume 1, pp 1-8; doi:10.3816/cbc.2011.n.011

Yusuke Matsui, Takao Hiraki, Hidefumi Mimura, Hideo Gobara, Daisaku Inoue, Tatsuhiko Iishi, , Susumu Kanazawa
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 51-55; doi:10.3816/clc.2011.n.007

The publisher has not yet granted permission to display this abstract.
Sylke Nagel, Olaf Kellner, Walburga Engel-Riedel, Sylvia Guetz, Christian Schumann, , Wolfgang Schuette
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 62-69; doi:10.3816/clc.2011.n.009

The publisher has not yet granted permission to display this abstract.
, Xiaoting Zhao, Lina Zhang, Shaofa Xu, Zhidong Liu, Li Ma, Wenyun Jia, Zhe Qian, Chunyan Zhang, Yue Wang, et al.
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 43-50; doi:10.3816/clc.2011.n.006

The publisher has not yet granted permission to display this abstract.
, Jeff Longmate, , Barbara Gitlitz, Athanassios Argiris, Suresh Ramalingam, , Philip C. Mack, Derick H.M. Lau, Mariana Koczywas, et al.
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 33-37; doi:10.3816/clc.2011.n.004

The publisher has not yet granted permission to display this abstract.
Wen Gao, Lingxiang Liu, Xiao Lu, Yongqian Shu
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 14-17; doi:10.3816/clc.2011.n.001

Arman Hasani, Natasha Leighl
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 18-25; doi:10.3816/clc.2011.n.002

The publisher has not yet granted permission to display this abstract.
, Raza Khan, Mohammad Jahanzeb
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 26-32; doi:10.3816/clc.2011.n.003

The publisher has not yet granted permission to display this abstract.
, Ian Collins, Lydia Forde, Bassel Al-Alao, Vincent Young, Michael Gerg, Friedrich Feuerhake, Kenneth O’Byrne
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 38-42; doi:10.3816/clc.2011.n.005

The publisher has not yet granted permission to display this abstract.
, , Yosuke Togashi, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Yuichi Sakamori, Tadashi Mio, Michiaki Mishima
Published: 1 January 2011
Clinical Lung Cancer, Volume 12, pp 56-61; doi:10.3816/clc.2011.n.008

The publisher has not yet granted permission to display this abstract.
, Steven M. Sugarman, Monica N. Fornier, Gabriella D'andrea, Teresa Gilewski, Diana Lake, Tiffany Traina, Carolyn Wasserheit-Lieblich, Nancy Sklarin, Deena Atieh-Graham, et al.
Published: 31 December 2010
Clinical Breast Cancer, Volume 10, pp 440-444; doi:10.3816/cbc.2010.n.057

The publisher has not yet granted permission to display this abstract.
, Anna Cardillo, Giuseppe Cancello, Silvia Dellapasqua, Alessandra Balduzzi, Raffaella Ghisini, Alberto Luini, , Giuseppe Viale, Aron Goldhirsch, et al.
Published: 31 December 2010
Clinical Breast Cancer, Volume 10, pp 483-488; doi:10.3816/cbc.2010.n.064

The publisher has not yet granted permission to display this abstract.
Published: 31 December 2010
Clinical Colorectal Cancer, Volume 9, pp 269-273; doi:10.3816/ccc.2010.n.039

The publisher has not yet granted permission to display this abstract.
, Antonio Jimeno, Heather Jacene, Ming Zhao, Piotr Kulesza, Daniel A. Laheru, Yasmin Kahn, Alexander Spira, Janet Dancey, Christine Iacobuzio-Donahue, et al.
Published: 31 December 2010
Clinical Colorectal Cancer, Volume 9, pp 297-304; doi:10.3816/ccc.2010.n.043

The publisher has not yet granted permission to display this abstract.
José Baselga, Sandra M. Swain
Published: 31 December 2010
Clinical Breast Cancer, Volume 10, pp 489-491; doi:10.3816/cbc.2010.n.065

The publisher has not yet granted permission to display this abstract.
Allyson J. Ocean, Blase Polite, Paul Christos, , Anne Hamilton, Daniel Matulich, Helen X. Chen, , Hedy L. Kindler
Published: 1 December 2010
Clinical Colorectal Cancer, Volume 9, pp 290-296; doi:10.3816/CCC.2010.n.042

Abstract:
The bevacizumab-cetuximab combination has shown promising activity in chemotherapy-refractory metastatic colorectal cancer (mCRC). We sought to determine the safety and efficacy of cetuximab added to bevacizumab plus standard mFOLFOX6 (modified 5-fluorouracil [5-FU]/leucovorin/oxaliplatin) as first-line therapy for mCRC. Sixty-six patients received cetuximab (400 mg/m2 loading dose, then 250 mg/m2 weekly intravenously [I.V.]) plus bevacizumab 5 mg/kg and mFOLFOX6 chemotherapy every 2 weeks. The primary endpoint was toxicity. The most common grade 3-4 events included diarrhea (14%), fatigue (14%), neuropathy (12%), venous thrombosis (9%), acneiform rash (8%), and desquamation (8%). A protocol-defined prohibitive adverse event occurred in 4 patients (6%), including 2 treatment-associated deaths. Thirty-seven patients (56%) discontinued therapy before disease progression because of either toxicity (n = 19; 29%) or patient withdrawal (n = 18; 27%). Twenty-eight of 37 patients (76%) who discontinued therapy before disease progression did so because of cetuximab-associated toxicity. Although the addition of cetuximab to bevacizumab plus mFOLFOX6 was not associated with excessive life-threatening toxicity, many patients discontinued therapy because of cetuximab-associated toxicity. Taken together with the results of recently reported phase III trials, cetuximab should not be used concurrently with bevacizumab and infusional 5-FU, leucovorin, and oxaliplatin chemotherapy for the treatment of mCRC.
, David C. Seldin, , , Gheorghe Doros, Martha Skinner
Clinical Lymphoma Myeloma and Leukemia, Volume 10, pp 469-472; doi:10.3816/clml.2010.n.081

The publisher has not yet granted permission to display this abstract.
Min-Jia Zhang, Li Xiao, Yu-Hua Zhu, Jian-Jun Jiang, Mao-Song Jiang, Wei He
Clinical Lymphoma Myeloma and Leukemia, Volume 10, pp 477-479; doi:10.3816/clml.2010.n.083

The publisher has not yet granted permission to display this abstract.
Clinical Lymphoma Myeloma and Leukemia, Volume 10, pp 480-483; doi:10.3816/clml.2010.n.084

The publisher has not yet granted permission to display this abstract.
Jorge E. Cortes
Clinical Lymphoma Myeloma and Leukemia, Volume 10, pp 484-485; doi:10.3816/clml.2010.n.085

, Vito Leopoldo Troilo, , Anna Napoli, , Fernando Fischetti, Tommaso Berardi
Published: 1 December 2010
Clinical Breast Cancer, Volume 10, pp 445-451; doi:10.3816/cbc.2010.n.058

The publisher has not yet granted permission to display this abstract.
, Christopher Wynne, Guillermo Ramirez, Weili He, Yang Song, Yuliya Berd, Hongwei Wang, Anish Mehta, Antonio Lombardi
Published: 1 December 2010
Clinical Breast Cancer, Volume 10, pp 452-458; doi:10.3816/cbc.2010.n.059

The publisher has not yet granted permission to display this abstract.
Stephen R.D. Johnston
Published: 1 December 2010
Clinical Breast Cancer, Volume 10, pp 419-420; doi:10.3816/cbc.2010.n.066

, Clarissa De Cerqueira Mathias, Florencia Perazzo, Sergio D. Simon, Luis Fein, Jorge Hidalgo, Andre M. Murad, Regina Esser, Stefanie Senger, Guillermo Lerzo
Published: 1 December 2010
Clinical Colorectal Cancer, Volume 9, pp 282-289; doi:10.3816/ccc.2010.n.041

The publisher has not yet granted permission to display this abstract.
, Michael A. Carducci
Published: 1 December 2010
Clinical Genitourinary Cancer, Volume 8, pp 37-46; doi:10.3816/cgc.2010.n.006

Vicente Valero, Amanda L. Kong, Kelly K. Hunt, , Rosa F. Hwang, Funda Meric-Bernstam, Isabelle Bedrosian, Merrick I. Ross, Gildy V. Babiera, Jennifer K. Litton, et al.
Published: 1 December 2010
Clinical Breast Cancer, Volume 10, pp 477-482; doi:10.3816/cbc.2010.n.063

The publisher has not yet granted permission to display this abstract.
Published: 1 December 2010
Clinical Colorectal Cancer, Volume 9, pp 274-281; doi:10.3816/ccc.2010.n.040

The publisher has not yet granted permission to display this abstract.
, Sheila Garcia, Amar M. Panchal, Joann Lim, David S. Hong, Chaan Ng, , , Isis Gayed, Razelle Kurzrock
Published: 1 December 2010
Clinical Colorectal Cancer, Volume 9, pp 311-314; doi:10.3816/CCC.2010.n.045

Abstract:
This pilot clinical trial explored the feasibility, safety, and efficacy of regional hepatic therapy combined with systemic anticancer agents in patients with refractory solid tumors and extensive unresectable liver involvement, including those with compromised hepatic function. Six patients with colorectal (N = 3), ovarian (N = 2), and hepatocellular carcinoma (N = 1) received intra-arterial hepatic oxaliplatin followed by intravenous 5-fluorouracil, leucovorin, and bevacizumab every 2 weeks until disease progression. All had extensive liver metastases; four had elevated baseline serum total bilirubin. Median total bilirubin was 2.8 mg/dL (range, 0.2-5.2 mg/dL). Median Child-Pugh score was 7 (range, 5-10). Thirty treatments were delivered (2-7 per patient). Median age of patients was 57 years (range, 25-69 years). Three patients (1 with colorectal, 1 with hepatocellular, and 1 with ovarian cancer) attained partial responses. Two had failed previous oxaliplatin and cisplatin treatment. Some with elevated bilirubin at baseline had a significant drop in bilirubin with treatment (bilirubin 5.2 → 1 mg/dL, 4.8 → 1.1 mg/dL, and 5.2 → 1.8 mg/dL). The regimen was generally well tolerated; the most common side effects were grade 1 fatigue, anorexia, and/or hypertension. One patient died of enzyme-linked, immunoassay-confirmed, heparin-induced thrombocytopenia during the sixth cycle of therapy. At doses tested, this regimen was safe and demonstrated antitumor activity in patients with advanced refractory malignancies involving the liver, including those with hepatic insufficiency. Further study is warranted.
, Philip J. Saylor, Matthew R. Smith
Published: 1 December 2010
Clinical Genitourinary Cancer, Volume 8, pp 29-36; doi:10.3816/CGC.2010.n.005

Abstract:
Skeletal complications are major causes of morbidity in patients with prostate cancer. Despite the osteoblastic appearance of prostate cancer bone metastases, elevated serum and urinary markers of bone resorption are indicative of high osteoclast activity. Increased osteoclast activity is independently associated with subsequent skeletal complications, disease progression, and death. Osteoclast-targeted therapies aim to reduce the risk for disease-related skeletal complications, bone metastases, and treatment-related fractures. This review focuses on recent advances in osteoclast-targeted therapies in the treatment and prevention of bone complications in prostate cancer. Osteoclast-targeted therapies have been extensively studied in men with prostate cancer. The potent bisphosphonate zoledronic acid significantly decreased the risk of skeletal complications in men with castration-resistant prostate cancer and bone metastases, and is Federal Drug Administration approved for this indication. Denosumab is a human monoclonal antibody that inhibits receptor activator of nuclear factor-κB (RANK) ligand, a critical mediator of osteoclast differentiation, activation, and survival. Data from recent phase III clinic trials demonstrate the emerging role for denosumab in the treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy.
Christopher R. Flowers, James O. Armitage
Clinical Lymphoma Myeloma and Leukemia, Volume 10, pp 414-423; doi:10.3816/clml.2010.n.086

The publisher has not yet granted permission to display this abstract.
Clinical Lymphoma Myeloma and Leukemia, Volume 10, pp 424-442; doi:10.3816/clml.2010.n.076

The publisher has not yet granted permission to display this abstract.
, Hagop Kantarjian, , Aarati Ranganathan,
Clinical Lymphoma Myeloma and Leukemia, Volume 10, pp 443-451; doi:10.3816/clml.2010.n.077

The publisher has not yet granted permission to display this abstract.
Page of 62
Articles per Page
by
Show export options
  Select all
Back to Top Top